WuXi AppTec released its performance for the first three quarters, with a net profit attributable to the parent company of 12.076 billion yuan, a year-on-year increase of 84.84%

According to the Zhitong Finance APP, WuXi AppTec (603259.SH) released its Q3 2025 report. In the first three quarters, the company achieved operating revenue of RMB 32.857 billion, a year-on-year increase of 18.61%. The net profit attributable to shareholders of the listed company was RMB 12.076 billion, a year-on-year increase of 84.84%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was RMB 9.522 billion, a year-on-year increase of 42.51%.

The report shows that the chemical business achieved revenue of RMB 25.98 billion, a year-on-year increase of 29.3%. The small molecule drug discovery ("R", Research) business continues to drive downstream. In the past twelve months, the company successfully synthesized and delivered over 430,000 new compounds for customers. At the same time, 250 molecules were converted from R to D in the first three quarters of 2025. The company implements the strategies of "following customers" and "following molecules," establishing trustworthy partnerships with global clients, laying a solid foundation for the continuous growth of its CRDMO business.

The small molecule process R&D and production ("D" and "M", Development and Manufacturing) business maintained strong growth. The small molecule CDMO pipeline continues to expand. Revenue from small molecule D&M business reached RMB 14.24 billion, a year-on-year increase of 14.1%. In the first three quarters of 2025, the small molecule D&M pipeline added a total of 621 new molecules. As of the end of September 2025, the total number of small molecule D&M pipelines reached 3,430, including 80 commercialization projects, 87 clinical phase III projects, 374 clinical phase II projects, and 2,889 preclinical and clinical phase I projects. A total of 15 projects were added in the commercialization and clinical phase III stages in the first three quarters of 2025. The company continues to promote small molecule capacity construction. In March 2025, both the Changzhou and Taixing API bases successfully passed FDA on-site inspections with zero defects. It is expected that by the end of 2025, the total volume of small molecule API reactors will exceed 4,000 kL.

The TIDES business (oligonucleotides and peptides) maintained rapid growth. With the new production capacity from last year ramping up quarter by quarter, TIDES business revenue reached RMB 7.84 billion in the first three quarters of 2025, a year-on-year increase of 121.1%. As of the end of September 2025, TIDES orders on hand increased by 17.1% year-on-year. The number of customers served by TIDES D&M services increased by 12% year-on-year, and the number of molecules served increased by 34% year-on-year. In September 2025, the company completed the peptide capacity construction in Taixing ahead of schedule, and the total volume of its peptide solid-phase synthesis reactors has been increased to over 100,000 L